Methods of treating ovarian cancer with hemp extract

Patent metadata

Field	Value
Publication number	US-12440528-B2
Application number	US-202418635597-A
Country	US
Kind code	B2
Filing date	Apr 15, 2024
Priority date	Oct 26, 2021
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

Methods for treating ovarian cancer comprising: administering to a patient and effective amount of a cannabis extract comprising CBD wherein preferably the cannabis extract is administered via a mucosal formulation.

First claim

What is claimed is:

1. A method for treating ovarian cancer comprising:
a. administering to a patient an amount of a composition comprising a cannabis extract (CE) and a reduced amount of a chemotherapeutic agent as compared to a recommended amount of the chemotherapeutic agent;
b. wherein the chemotherapeutic agent is selected from the group consisting of: paclitaxel, altretamine, capecitabine, cyclosphosphamide, etoposide, gemcitabine, ifosfamide, itinotecan, doxorubicin, melphalan, pemetrexed, topotecan, binorelbine, carboplatin, cisplatin, docetaxel, and combinations thereof; and
c. wherein the composition comprising the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE and has a pH of between 3.5 and 6, said composition further comprising at least one additional cannabinoid present at between 0.1% and 10% by weight of the CE selected from the group consisting of:
Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (48-THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

2. The method of claim 1 wherein the CE is a full spectrum cannabis extract (FSHE) or a broad spectrum cannabis extract (BSHE).

3. The method of claim 1 wherein the ovarian cancer is a malignant ovarian cancer.

4. The method of claim 1 wherein the reduced amount of the chemotherapeutic agent is five times less than the recommended amount.

5. The method of claim 1 wherein the reduced amount of the chemotherapeutic agent is six times less than the recommended amount.

6. The method of claim 1 wherein the reduced amount of the chemotherapeutic agent is 2.5 times less than the recommended amount.

7. The method of claim 1 wherein the CE is administered orally, via mucosa, by injection, or by combinations thereof.

8. The method of claim 1 further comprising determining the amount of CE to be administered to the patient and the reduced amount of the chemotherapeutic agent to be administered to the patient that produces an expected clinical response equivalent to an expected clinical response of the recommended amount of the chemotherapeutic agent alone.

9. The method of claim 8 wherein determining the amounts of CE and chemotherapeutic agent to be administered to the patient is based on results obtained via three-dimensional cell or organoid screening, animal model screening, or both.

10. The method of claim 1 wherein the composition comprising the cannabis extract comprises:
a carrier, said carrier being between 1% and 90% by weight of the composition and wherein the CE is between 1% and 99% by weight of the composition.

11. The method of claim 10 wherein the composition further comprises at least one terpene selected from the group consisting of: β-myrcene, β-caryophyllene, linalool, α-pinene, citral, D-limonene, eucalyptol, and combinations thereof.

12. The method of claim 10 wherein the composition further comprises at least one polyphenol selected from the group consisting of: a catechin, quercetin, cannflavin A/B/C, rutin, chlorogenic acid, and combinations thereof.

13. The method of claim 10 wherein the composition further comprises at least one fatty acid selected from the group consisting of: an omega 3 acid, an omega 6 acid, an omega 9 acid, and combinations thereof.

14. The method of claim 10 wherein the composition further comprises at least one phytonutrient wherein the phytonutrient is selected from the group consisting of: a tocopherol, a sterol, carotene, an aliphatic alcohol, a mineral, and combinations thereof.

15. The method of claim 1 wherein the CE is a broad spectrum hemp extract (BSHE) or a full spectrum hemp extract (FSHE) and wherein each of the BSHE or FSHE comprises 50% to 99% by weight of CBD.

16. The method of claim 15 wherein the CE comprises CBD at a concentration of between 60% and 99% and at least one other cannabinoid selected from the group consisting of: Δ 9 -THC, THCA, THCV, Δ 8 -THC, CBC, CBCA, CBG, CBGA, CBDA, CBDV, CBN, CBL, and combinations thereof; and wherein the CE comprises a total concentration of cannabinoids of between 65% and 99% by weight.

17. The method of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% of a total weight of the composition.

18. The method of claim 1 wherein the composition comprises an oil or a fat as a carrier.

19. The method of claim 1 wherein the chemotherapeutic agent and the CE are administered as one composition or as two different compositions.

20. The method of claim 1 wherein the ovarian cancer is a chemoresistant cancer.

21. The method of claim 1 wherein the reduced amount of the chemotherapeutic agent is at least 50% less than a recommended individual dose and wherein the CE is administered at between 20 mg and 4,250 mg per day.

22. The method of claim 1 wherein a cannabinoid profile of the CE comprises cannabidiol (CBD) at between about 70% and about 99% by weight, cannabigerol (CBG) at between about 0.1% and about 3.5% by weight, cannabinol (CBN) at between about 0.01% and about 0.5% by weight, and total tetrahydrocannabinol (THC) at between 0% and about 1.5% by weight.

23. The method of claim 1 wherein a cannabinoid profile of the CE comprises cannabidiol (CBD) at between about 65% and about 98% by weight, cannabigerol (CBG) at between about 0.1% and about 3.5% by weight, cannabinol (CBN) at between about 0.01% and about 0.5% by weight, total tetrahydrocannabinol (THC) at between about 0.3% and about 5% by weight, cannabichromene (CBC) at between about 0.0% and about 3.5% by weight, and cannabidivarin (CBDV) at between about 0% and about 2.5% by weight.

24. The method of claim 1 wherein a cannabinoid profile of the CE comprises from about 0.1% to about 10% of cannabidiolic acid (CBDA).

25. The method of claim 1 wherein a cannabinoid profile of the CE comprises a cannabidiolic acid (CBDA) isolate.

26. The method of claim 1 wherein administering the reduced amount of the chemotherapeutic agent comprises administering a reduced individual dose, a reduced number of cycles, or both.

Assignees

• Ecofibre Usa Inc
• Univ Newcastle

Inventors

• Capano Alexandra M
• Tanwar Pradeep Singh
• Nance Alex

Classifications

• A61K36/3482 Primary

  Cannabis · CPC title

• A61K31/658 Primary

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title